Structured around creation of new drugs for treatment of airway diseases such as asthma, COPD, and other respiratory viral infections, NuPeak Therapeutics Inc. is a biotechnology company conducting all aspects of the drug discovery and development to include basic science, structure-based drug design, cell and animal preclinical testing, pharmacology-toxicology, and human clinical trials. Firm's founder had started a drug discovery program at WU in 2009 that runs in concert with NuPeak Therapeutics. Together program is structured around discovering/ developing small-molecule-kinase inhibitors to correct epithelial stem cell and innate immune cell reprogramming in the settings of post-viral inflammation and in cancer. University focuses on the drug discovery phase using cell and animal models combined with medicinal chemistry and molecular pharmacology to move from structure-based drug design to proof of concept. Nupeak concentrates on drug development phase safety to deliver toxicology data for IND approval and initial clinical trials in humans. Current proprietary lead compounds are designed for the progressive post-viral respiratory disease found in asthma, COPD, and COVID-19 and for correcting related pathways found in breast, liver, and brain cancers.
